Treatment Modalities for Aromatase Inhibitor-Associated Musculoskeletal Syndrome (AIMSS): A Scoping Review of Prospective Treatment Studies
Abstract
Aromatase inhibitors (AI's) are effective adjuvant treatments for postmenopausal patients with hormone receptor-positive breast cancer. However, AIs are often associated with diffuse joint and muscle pain, referred to as aromatase inhibitor-associated musculoskeletal syndrome (AIMSS), the symptoms of which are associated with negative impacts and reduced adherence to AI therapy. As more interventions for AIMSS continue to be investigated, a scoping review is needed to survey and summarize the types of interventions and outcomes assessed in studies conducted to date, which may help identify areas needing attention or additional focus in future research. Online databases were searched (from inception to January 8, 2025) to identify 74 reports from prospective studies of interventions for AIMSS pain, stiffness, or interference with functioning. Such interventions were classified as pharmacological (14 reports), complementary/alternative (43 reports), or rehabilitative (17 reports). Included papers required the presence of AIMSS symptoms at enrollment. Several interventions were deemed promising for reducing AIMSS symptoms based on positive results from individual reports, including duloxetine (3 reports from 2 studies), vitamin B12 (2 reports), vitamin D (2 reports), calcitonin (1 report), prednisolone (1 report), glucosamine and chondroitin (1 report), various mind-body (14 reports from 12 studies) and traditional medicine interventions (3 reports), and switching to another AI…
Read the paper
Related studies
- Promising Sources of Plant-Derived Polyunsaturated Fatty Acids: A Narrative Review
- Effects of omega-3 polyunsaturated fatty acid intake in patients with chronic kidney disease: Systematic review and meta-analysis of randomized controlled trials
- Effect of omega-3 fatty acids on cognition: an updated systematic review of randomized clinical trials
- The role of omega-3 polyunsaturated fatty acid supplementation in the management of type 2 diabetes mellitus: A narrative review
- Paucity of evidence for a relationship between long-chain omega-3 fatty acid intake and chronic obstructive pulmonary disease: a systematic review
- Omega-3 fatty acid nanocarriers: Characterization and potential applications
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.